Stanford Medicine researchers have identified a naturally occurring molecule that may suppress appetite and reduce body weight in a way that resembles semaglutide, the active ingredient in Ozempic. In animal studies, the molecule also appeared to avoid several problems associated with the drug, including nausea, constipation and substantial muscle loss. This groundbreaking discovery, powered by advanced artificial intelligence, could herald a new era in the treatment of obesity and metabolic disorders, offering a more targeted and potentially gentler approach to weight management.
The molecule, designated BRP, operates through a distinct yet related metabolic pathway compared to semaglutide. Crucially, it activates a separate group of neurons in the brain. This divergence in mechanism is a key factor that researchers believe could lead to a more precise tool for controlling appetite and body weight, minimizing the widespread systemic effects that can accompany existing therapies.
A More Targeted Approach to Appetite Regulation
The significance of BRP’s specific mechanism lies in its apparent action within the hypothalamus, a critical region of the brain responsible for regulating fundamental bodily functions including hunger, thirst, body temperature, and energy expenditure. "The receptors targeted by semaglutide are found in the brain but also in the gut, pancreas and other tissues," explained Dr. Katrin Svensson, assistant professor of pathology at Stanford Medicine and senior author of the study. "That’s why Ozempic has widespread effects including slowing the movement of food through the digestive tract and lowering blood sugar levels. In contrast, BRP appears to act specifically in the hypothalamus, which controls appetite and metabolism."
The hypothalamus, a small but vital area deep within the brain, orchestrates a complex symphony of signals that influence our drive to eat and how our bodies utilize energy. By focusing its effects primarily on this region, BRP may offer a way to modulate appetite without triggering the cascade of unintended consequences often observed with drugs that have a broader reach throughout the body. This specificity is a highly sought-after characteristic in drug development, aiming to maximize therapeutic benefit while minimizing adverse effects.
Dr. Svensson, recognizing the profound potential of this discovery, has co-founded a company poised to advance BRP into human clinical trials in the near future. This transition from preclinical research to human testing represents a significant milestone, bringing the molecule closer to potential therapeutic application. The research detailing this discovery was published on March 5th in the prestigious journal Nature, with Dr. Laetitia Coassolo, a senior research scientist at Stanford Medicine, serving as the lead author of the study.
The Power of Artificial Intelligence in Uncovering Hidden Peptides
The identification of BRP was not a serendipitous accident but a testament to the power of cutting-edge artificial intelligence. AI played an indispensable role in enabling researchers to systematically sift through vast quantities of data related to proteins, specifically a class known as prohormones.
Prohormones are essentially inactive precursor molecules. Their biological function is only realized when specialized enzymes cleave them into smaller fragments called peptides. These peptides can then act as signaling molecules, or hormones, carrying vital messages that influence a wide array of complex processes in the brain and throughout the body, including metabolism and appetite.
The challenge in this field is immense. A single prohormone can be processed in numerous ways, yielding a multitude of potential peptides. Distinguishing the truly biologically significant peptide hormones from the large number of ordinary fragments generated during normal protein turnover and breakdown is a formidable task. Traditional laboratory methods, while effective, can generate enormous datasets, requiring researchers to meticulously analyze hundreds of thousands of molecules to pinpoint those with meaningful physiological effects. This process is often time-consuming and resource-intensive.
Searching for Novel Metabolic Signals
The Stanford team strategically focused their investigation on an enzyme named prohormone convertase 1/3 (PC1/3). This enzyme is known to cleave prohormones at specific amino acid sequences, and previous research has already established a link between alterations in PC1/3 activity and obesity in humans. This provided a critical starting point for their search for new metabolic signals.
Among the peptides known to be produced by PC1/3 is glucagon-like peptide 1 (GLP-1). GLP-1 is a well-established hormone that plays a crucial role in regulating hunger and blood sugar levels. Semaglutide, the active ingredient in popular weight-loss medications like Ozempic and Wegovy, functions by mimicking and amplifying the effects of GLP-1 in the body. Recognizing the profound impact of GLP-1, the researchers hypothesized that PC1/3 might be responsible for generating other, as yet undiscovered, peptides with similar or complementary effects on energy balance and appetite.
Peptide Predictor: An AI-Driven Discovery Engine
To systematically explore this hypothesis, the researchers turned to artificial intelligence, developing a sophisticated computer algorithm they aptly named "Peptide Predictor." This innovative tool was designed to revolutionize the discovery process, moving beyond the laborious manual extraction of proteins and peptides from tissues followed by time-consuming analysis using techniques like mass spectrometry.
Peptide Predictor was tasked with scanning all 20,000 human protein-coding genes. Its objective was to identify the specific types of sites where prohormone convertases, like PC1/3, typically cleave proteins. The search was further refined by focusing on genes that produce proteins secreted outside the cell – a characteristic common to hormones – and that possessed at least four potential cleavage sites. This rigorous filtering process dramatically narrowed down the vast landscape of human genes to a more manageable group of 373 prohormones.
"The algorithm was absolutely key to our findings," Dr. Svensson emphasized, underscoring the transformative impact of AI on their research trajectory.
The algorithm then predicted that PC1/3 could generate an estimated 2,683 distinct peptides from these 373 prohormones. With this extensive list, Dr. Coassolo and Dr. Svensson directed their attention to sequences that exhibited the highest probability of influencing brain function related to appetite and metabolism.
From this refined list, they selected 100 peptides, including the already known GLP-1, for experimental testing. Their initial validation involved assessing whether these peptides could stimulate neuron-like cells cultured in the laboratory.
A Tiny Peptide with an Outsized Impact
As anticipated, GLP-1 demonstrated a robust ability to activate the neuronal cells, increasing their activity by approximately threefold compared to untreated control cells. However, it was a much smaller peptide that produced an even more remarkable response. This peptide, later identified as BRP, is composed of a mere 12 amino acids. Despite its diminutive size, BRP boosted neuronal activity by a staggering tenfold increase compared to the controls.
The researchers named this potent peptide BRP, derived from its parent prohormone, BPM/retinoic acid inducible neural specific 2, or BRINP2 (BRINP2-related-peptide). Amino acids are the fundamental building blocks of proteins and peptides. A molecule consisting of only 12 amino acids is exceptionally small when compared to most full-length proteins. Yet, BRP’s disproportionately powerful effect in these initial cell-based tests signaled its exceptional potential.
Promising Results in Preclinical Models: Food Intake Reduced, Fat Loss Observed
Encouraged by the in vitro findings, the research team proceeded to test BRP in animal models. Their studies included both lean mice and minipigs, the latter chosen for their metabolic and eating patterns that more closely mirror those of humans than mice alone.
In these studies, an intramuscular injection of BRP administered shortly before feeding led to a significant reduction in food intake. In both species, food consumption decreased by as much as 50% within the hour following the injection. This immediate impact on appetite suggested a potent and rapid mechanism of action.
Furthermore, the team conducted a longer-term study involving obese mice. For 14 consecutive days, these mice received daily BRP injections. The results were compelling: on average, the treated animals lost 3 grams, with the vast majority of this loss attributed to a reduction in body fat. In contrast, the control group of obese mice gained approximately 3 grams over the same period, highlighting BRP’s efficacy in promoting weight loss and reversing weight gain in a preclinical setting.
Beyond weight reduction, the BRP-treated mice also exhibited improvements in glucose and insulin tolerance. These physiological markers are critical indicators of metabolic health, reflecting the body’s efficiency in regulating blood sugar and its sensitivity to insulin, the hormone essential for glucose uptake by cells. Improved glucose and insulin tolerance suggest that BRP may not only help with weight management but also contribute to better overall metabolic control, potentially reducing the risk of type 2 diabetes.
Addressing Side Effects: A Potential Advantage Over Existing Therapies
A particularly encouraging aspect of the BRP research is the apparent absence of several common side effects associated with semaglutide and other weight-loss medications. Behavioral testing in the animal models revealed no significant differences between the BRP-treated and untreated groups in terms of movement, water consumption, anxiety-like behavior, or fecal production.
The lack of any notable change in fecal production is especially significant. Constipation, a common and often bothersome side effect of semaglutide, arises from its effect of slowing down the digestive tract. The absence of this symptom in BRP-treated animals suggests a potentially more favorable gastrointestinal profile. Moreover, the researchers did not observe any responses indicative of nausea, another frequent complaint associated with GLP-1 receptor agonists, nor did they note any substantial muscle loss, which can be a concern with rapid weight loss achieved through other means.
Additional analyses of brain activity and overall body function further supported the notion that BRP operates through distinct metabolic and neuronal pathways compared to GLP-1 or semaglutide. This divergence in mechanism is believed to be the underlying reason for BRP’s potentially more focused action and its reduced propensity for eliciting common side effects. While these findings are currently limited to animal studies, they offer a strong foundation for optimism regarding BRP’s safety profile in humans.
Future Directions and Challenges Ahead
Despite the promising preclinical results, several critical questions remain as researchers prepare for human trials. A primary focus is on identifying the specific cell-surface receptors to which BRP binds. Receptors are the molecular docking stations that receive signals from hormones, drugs, and other chemical messengers. Pinpointing the exact receptor for BRP will be instrumental in understanding the precise molecular mechanisms by which it influences appetite and metabolism.
The team also aims to comprehensively map the cascade of events that occurs after BRP successfully binds to its target receptor. This detailed understanding will provide deeper insights into its biological impact and potential therapeutic applications.
Another significant challenge lies in the duration of BRP’s action. Small peptides, like BRP, are often rapidly broken down by enzymes in the body, which can limit their therapeutic effect. Researchers are actively exploring strategies to enhance the stability and longevity of BRP, aiming to develop formulations that allow for a more practical and convenient dosing schedule for future human use.
"The lack of effective drugs to treat obesity in humans has been a problem for decades," Dr. Svensson stated, reflecting on the urgent need for novel therapeutic solutions. "Nothing we’ve tested before has compared to semaglutide’s ability to decrease appetite and body weight. We are very eager to learn if it is safe and effective in humans."
The journey from laboratory discovery to approved medication is a long and complex one, involving rigorous testing and regulatory scrutiny. However, the discovery of BRP represents a significant leap forward in the quest for more effective and better-tolerated treatments for obesity and related metabolic conditions. The potential for a molecule that can suppress appetite and reduce weight without the widespread side effects of current therapies offers a beacon of hope for millions worldwide grappling with these chronic health challenges.
The research was a collaborative effort, with contributions from researchers at the University of California, Berkeley; the University of Minnesota; and the University of British Columbia. Funding for this groundbreaking work was provided by a consortium of esteemed institutions, including the National Institutes of Health, the SPARK Translational Research Program at Stanford, Stanford Bio-X, the Stanford Maternal and Child Health Research Institute, the American Heart Association, a Stanford Medicine Dean’s Fellowship Award, the Carlsberg Foundation, and the Wu Tsai Human Performance Alliance. Dr. Svensson and Dr. Coassolo are listed as inventors on patents pertaining to BRP peptides for metabolic disorders, and Dr. Svensson is a co-founder of Merrifield Therapeutics, a company that will likely be central to the further development and commercialization of this promising new molecule.
